
Conference Coverage
Latest Content

Medicaid Expansion Associated With Lower Mortality in NSCLC

Most Americans Pleased With Health Insurance Options for 2026

Polarized Dermatoscopes Improve Teledermoscopy Image Quality but Raise Cost Barriers

Angiogenesis Inhibitors Not Linked to Arterial Dissections, Aneurysms in Colorectal Cancer

Political Ideology Impacts Trust in Scientists for Cancer Information
Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Explore the evolving landscape of biologics in metabolic syndrome treatment, highlighting GLP-1 analogs and PCSK9 inhibitors for improved patient outcomes.

Prerna Mewawalla, MD, discusses innovative strategies to enhance cancer care access, reduce clinician burden, and improve clinical trial diversity in real-world settings.

Children with lower redemption of key WIC foods are more likely to discontinue participation before age 3, study finds.

Self-pay emergency department prices rose significantly from 2021 to 2023, especially at for-profit and system-affiliated hospitals, highlighting growing affordability challenges for uninsured and underinsured patients.

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.

A study finds that community oncology practices limit financial toxicity for patients with cancer, offering significant cost savings compared with hospital outpatient settings.

Guideline-recommended HF therapies do not improve major outcomes in Chagas disease, though sacubitril/valsartan improved NT-proBNP levels, new data show.

A study reveals real-world effects of switching to adalimumab biosimilar Hyrimoz, highlighting flare rates and injection pain concerns in inflammatory disease patients.

Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.

Pirtobrutinib is now fully approved for CLL/SLL in those previously treated with Bruton tyrosine kinase inhibitors.



























































